首页> 外文OA文献 >Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study

【2h】

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study

机译：Filgotinib（GLPG0634 / GS-6034），一种口服JAK1选择性抑制剂，与活动性类风湿性关节炎且对MTX反应不足的患者有效结合甲氨蝶呤（MTX）：一项随机的剂量研究研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Westhovens, R; Taylor, P; Alten, R; Pavlova, D; Enriquez-Sosa, F; Mazur, M; Greenwald, M; Van der Aa, A; Vanhoutte, F; Tasset, C; Harrison, P;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) [J] . Westhovens R., Taylor P. C., Alten R., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第6期

机译：菲尔替尼（GLPG0634 / GS-6034）是口腔jak1选择性抑制剂，与甲氨蝶呤（MTX）组合有效的类风湿性关节炎，对MTX的反应不充分：随机剂量寻找研究（Darwin 1）的结果
2. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) [J] . Kavanaugh A., Kremer J., Ponce L., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第6期

机译：Filgotinib（GLPG0634 / GS-6034）是一种口服选择性JAK1抑制剂，作为活性类风湿性关节炎患者的单一疗法是有效的：来自随机，剂量寻找研究的结果（Darwin 2）
3. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). [J] . Emery P, Deodhar A, Rigby WF, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2010,第9期

机译：不同剂量的利妥昔单抗的疗效和安全性以及复治的利妥昔单抗：一项针对具有生物学活性的类风湿性关节炎且对甲氨蝶呤反应不充分的患者的安慰剂对照随机对照试验（研究评估利妥昔单抗在MTX iN不足的rEsponders（SERENE）中的疗效）。
4. Extended report: Efficacy and safety of different doses and retreatment of rituximab: a randomised placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabs Efficacy in MTX iNadequate rEsponders (SERENE)) [O] . P Emery, A Deodhar, W F Rigby, -1

机译：扩展报告：不同剂量的利妥昔单抗的有效性和安全性以及利妥昔单抗的再治疗：一项针对患有类风湿性关节炎且生物学上尚不成熟且对甲氨蝶呤反应不充分的患者的安慰剂对照试验（研究评估利妥昔单抗在MTX中的有效性rEsponder不足（SERENE））
5. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [O] . Emery, P, Deodhar, A, Rigby, W F, 2010

机译：不同剂量利妥昔单抗的有效性和安全性以及复治的利妥昔单抗：一项针对尚无活动性类风湿性关节炎且对甲氨蝶呤反应不充分的生物学初治患者的随机安慰剂对照试验（研究评估利妥昔单抗在MTX iR剂量不足反应剂（SERENE）中的疗效）

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study

著录项

相似文献

相关主题

期刊订阅